Send to

Choose Destination
See comment in PubMed Commons below
J Vet Sci. 2016 Dec 30;17(4):453-458. doi: 10.4142/jvs.2016.17.4.453.

Paclitaxel inhibits the hyper-activation of spleen cells by lipopolysaccharide and induces cell death.

Author information

  • 1Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University, Jeju 63243, Korea.


Paclitaxel was isolated from the bark of the Pacific yew, Taxus brevifolia, and used as an anticancer agent. Paclitaxel prevents cancer cell division by inhibiting spindle fiber function, inducing cell death. A recent study demonstrated that paclitaxel binds to myeloid differentiation protein-2 of Toll-like receptor 4 and prevents the signal transduction of lipopolysaccharide (LPS). Paclitaxel converts immune cells hypo-responsive to LPS. In this study, we investigated whether paclitaxel can inhibit the phenotype and function of immune cells. To accomplish this, we used spleen cells, a major type of immune cell, LPS, a representative inflammatory agent and a mitogen for B lymphocytes. LPS profoundly increased the activation and cytokine production of spleen cells. However, paclitaxel significantly inhibited LPS-induced hyper-activation of spleen cells. Furthermore, we found that paclitaxel induced cell death of LPS-treated spleen cells. These results suggest that paclitaxel can inhibit the hyper-immune response of LPS in spleen cells via a variety of mechanisms. These findings suggest that paclitaxel can be used as a modulating agent for diseases induced by hyper-activation of B lymphocytes. Taken together, these results demonstrate that paclitaxel inhibits the function of spleen cells activated by LPS, and further induces cell death.


cell death; hyper-activation; lipopolysaccharide; paclitaxel; spleen cells

[PubMed - in process]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for The Korean Society of Veterinary Science Icon for PubMed Central
    Loading ...
    Support Center